Rezolute IncNASDAQ:RZLT
- LAST PRICE4.8600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.8200/ 7
- Ask / Lots5.0800/ 1
- Open / Previous Close--- / 4.8600
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RZLT |
|---|---|---|
| 09:32 ET | 1433 | 5.01 |
| 09:33 ET | 316 | 5.09 |
| 09:35 ET | 600 | 5.07 |
| 09:39 ET | 1080 | 5.12 |
| 09:42 ET | 749 | 5.0985 |
| 09:50 ET | 398 | 5.02 |
| 09:51 ET | 19989 | 4.95 |
| 09:53 ET | 300 | 4.95 |
| 09:55 ET | 500 | 4.95 |
| 09:57 ET | 300 | 5 |
| 10:02 ET | 1218 | 4.97 |
| 10:04 ET | 7189 | 4.99 |
| 10:08 ET | 2278 | 4.99 |
| 10:09 ET | 1588 | 4.99 |
| 10:11 ET | 9421 | 4.93 |
| 10:13 ET | 2872 | 4.945 |
| 10:15 ET | 1200 | 4.96 |
| 10:18 ET | 700 | 4.95 |
| 10:20 ET | 1900 | 4.96 |
| 10:22 ET | 100 | 4.9594 |
| 10:24 ET | 100 | 4.96 |
| 10:26 ET | 2000 | 4.92 |
| 10:31 ET | 320 | 4.91 |
| 10:33 ET | 100 | 4.895 |
| 10:36 ET | 3273 | 4.91 |
| 10:38 ET | 150 | 4.93 |
| 10:40 ET | 1000 | 4.95 |
| 10:42 ET | 400 | 4.93 |
| 10:49 ET | 255 | 4.93 |
| 10:58 ET | 1200 | 4.93 |
| 11:02 ET | 100 | 4.93 |
| 11:03 ET | 1211 | 4.92 |
| 11:05 ET | 100 | 4.89 |
| 11:12 ET | 100 | 4.9 |
| 11:14 ET | 1557 | 4.925 |
| 11:16 ET | 200 | 4.925 |
| 11:18 ET | 3500 | 4.95 |
| 11:20 ET | 304 | 4.94 |
| 11:21 ET | 4574 | 4.9301 |
| 11:23 ET | 200 | 4.94 |
| 11:30 ET | 100 | 4.95 |
| 11:32 ET | 205 | 4.93 |
| 11:36 ET | 800 | 4.94 |
| 11:38 ET | 400 | 4.945 |
| 11:39 ET | 2095 | 4.94 |
| 11:41 ET | 260 | 4.93 |
| 11:43 ET | 100 | 4.93 |
| 11:45 ET | 402 | 4.94 |
| 11:52 ET | 100 | 4.94 |
| 11:54 ET | 500 | 4.95 |
| 11:56 ET | 605 | 4.95 |
| 11:59 ET | 200 | 4.95 |
| 12:01 ET | 100 | 4.95 |
| 12:03 ET | 6536 | 4.95 |
| 12:06 ET | 920 | 4.95 |
| 12:08 ET | 2850 | 4.95 |
| 12:10 ET | 101 | 4.945 |
| 12:12 ET | 2200 | 4.95 |
| 12:14 ET | 4274 | 4.95 |
| 12:15 ET | 100 | 4.945 |
| 12:17 ET | 200 | 4.95 |
| 12:19 ET | 9888 | 4.96 |
| 12:21 ET | 14726 | 4.96 |
| 12:24 ET | 500 | 4.955 |
| 12:26 ET | 487 | 4.96 |
| 12:30 ET | 150 | 4.9599 |
| 12:33 ET | 5300 | 4.96 |
| 12:35 ET | 7107 | 4.95 |
| 12:37 ET | 450 | 4.95 |
| 12:39 ET | 500 | 4.945 |
| 12:42 ET | 655 | 4.94 |
| 12:44 ET | 616 | 4.945 |
| 12:46 ET | 400 | 4.95 |
| 12:51 ET | 100 | 4.945 |
| 12:53 ET | 100 | 4.95 |
| 12:55 ET | 100 | 4.9425 |
| 12:57 ET | 200 | 4.945 |
| 01:02 ET | 100 | 4.94 |
| 01:04 ET | 879 | 4.945 |
| 01:06 ET | 500 | 4.95 |
| 01:08 ET | 600 | 4.94 |
| 01:09 ET | 100 | 4.945 |
| 01:11 ET | 100 | 4.95 |
| 01:15 ET | 100 | 4.945 |
| 01:22 ET | 1800 | 4.9464 |
| 01:31 ET | 3800 | 4.95 |
| 01:33 ET | 1400 | 4.95 |
| 01:40 ET | 200 | 4.945 |
| 01:42 ET | 2146 | 4.94 |
| 01:44 ET | 1628 | 4.94 |
| 01:49 ET | 1700 | 4.91 |
| 01:54 ET | 1300 | 4.91 |
| 01:56 ET | 400 | 4.9003 |
| 01:58 ET | 325 | 4.905 |
| 02:02 ET | 500 | 4.91 |
| 02:03 ET | 1793 | 4.9 |
| 02:07 ET | 101 | 4.9 |
| 02:09 ET | 900 | 4.9 |
| 02:12 ET | 500 | 4.89 |
| 02:14 ET | 300 | 4.88 |
| 02:18 ET | 400 | 4.84 |
| 02:20 ET | 900 | 4.87 |
| 02:21 ET | 500 | 4.86 |
| 02:23 ET | 300 | 4.865 |
| 02:25 ET | 240 | 4.88 |
| 02:27 ET | 100 | 4.865 |
| 02:30 ET | 100 | 4.865 |
| 02:32 ET | 100 | 4.88 |
| 02:34 ET | 641 | 4.885 |
| 02:38 ET | 715 | 4.87 |
| 02:39 ET | 2020 | 4.8665 |
| 02:41 ET | 500 | 4.86 |
| 02:43 ET | 2400 | 4.87 |
| 02:45 ET | 1311 | 4.86 |
| 02:48 ET | 450 | 4.86 |
| 02:50 ET | 102 | 4.86 |
| 02:52 ET | 400 | 4.8569 |
| 02:54 ET | 400 | 4.85 |
| 02:56 ET | 100 | 4.84 |
| 02:57 ET | 200 | 4.84 |
| 02:59 ET | 200 | 4.84 |
| 03:01 ET | 253 | 4.835 |
| 03:03 ET | 300 | 4.83 |
| 03:08 ET | 2692 | 4.87 |
| 03:10 ET | 360 | 4.84 |
| 03:19 ET | 1000 | 4.82 |
| 03:21 ET | 1900 | 4.851 |
| 03:24 ET | 1169 | 4.8443 |
| 03:26 ET | 1600 | 4.83 |
| 03:28 ET | 200 | 4.83 |
| 03:30 ET | 1412 | 4.85 |
| 03:32 ET | 746 | 4.84 |
| 03:33 ET | 842 | 4.85 |
| 03:35 ET | 2360 | 4.8715 |
| 03:37 ET | 1216 | 4.89 |
| 03:39 ET | 2200 | 4.87 |
| 03:42 ET | 200 | 4.86 |
| 03:44 ET | 4464 | 4.86 |
| 03:46 ET | 2550 | 4.86 |
| 03:48 ET | 377 | 4.87 |
| 03:50 ET | 1200 | 4.85 |
| 03:51 ET | 712 | 4.85 |
| 03:53 ET | 3702 | 4.85 |
| 03:55 ET | 1604 | 4.865 |
| 03:57 ET | 1994 | 4.855 |
| 04:00 ET | 21205 | 4.86 |
Nov 8, 2024
DJ Rezolute Price Target Maintained With a $14.00/Share by HC Wainwright & Co., from 11:40AM ET on Friday Nov 08, 2024 by Dow Jones
11:40AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
Press Release: Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow JonesRezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
Rezolute to Participate in Upcoming Investor Conferences, from 8:00AM ET on Tuesday Nov 05, 2024 by Dow Jones
8:00AM ET on Tuesday Nov 05, 2024 by Dow JonesDJ Rezolute Initiated at Outperform by Wedbush, from 4:50AM ET on Tuesday Nov 05, 2024 by Dow Jones
4:50AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Rezolute Inc | 281.6M | -3.8x | --- |
Tevogen Bio Holdings Inc | 279.9M | 4.4x | --- |
Aldeyra Therapeutics Inc | 286.4M | -6.4x | --- |
Atea Pharmaceuticals Inc | 274.5M | -1.6x | --- |
Lexicon Pharmaceuticals Inc | 279.0M | -1.0x | --- |
Nautilus Biotechnology Inc | 298.8M | -4.2x | --- |
Company Information
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Contact Information
- Headquarters
- 275 Shoreline Drive, Suite 500REDWOOD CITY, CA, United States 94065
- Phone
- 650-206-4507
- Fax
- 302-636-5454
Executives
- Acting Chairman of the Board, Chief Executive Officer
- Nevan Elam
- Chief Financial Officer
- Daron Evans
- Chief Medical Officer
- Brian Roberts
- Director
- Young-Jin Kim
- Independent Director
- Philippe Fauchet
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $281.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $-1.27 |
Book Value | $2.27 |
P/E Ratio | -3.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
